AVIR is trading at $4.06 (9.4% down) in pre-market. The company announced today the completion of patient enrollment in its Phase 3 C-FORWARD trial for Hepatitis C Virus, a key milestone for its antiviral pipeline.
- This follows a Q1 2026 earnings report in May where Atea Pharmaceuticals reported a narrower-than-expected net loss, beating analyst expectations.
- Despite these positive developments, the stock extends its recent decline, suggesting broader market sentiment or other factors are currently weighing on shares.